EUVIMEDEUVIMED entdecken
Crossref

Clinicopathologic features of non–type 1/2 gastric neuroendocrine tumors and their associated mucosal changes

Kristen Logan, Chanjuan Shi iD

American Journal of Clinical Pathology · 01.08.2023 · 160 (2) · 130-136

DOI: 10.1093/ajcp/aqad021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 06.04.2023. Verfasst von Kristen Logan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Duke University Medical Center, Durham, NC, US. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Stomach Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The pathogenesis for non–type 1/2 gastric neuroendocrine tumors (G-NETs) remains unclear. The aim of this study was to examine the clinicopathologic features of G-NETs and associated mucosal changes.

Methods

The electronic health records of patients with non–type 1/2 G-NETs were reviewed. H&E slides were reviewed for pathologic features and mucosal changes. The t test and Fisher exact test were used for statistical analysis.

Results

In total, 33 patients were assigned to either group 1 (n = 23) or group 2 (n = 10). Group 1 included patients with a history of proton pump inhibitor (PPI) use, increased gastrin levels, or significant PPI effect (PPI/gastrin-associated). All other patients were assigned to group 2. There was no significant difference in age and sex between the 2 groups. Group 2 tumors were more likely to be larger, invade deeper, and develop metastases (P < .05). Tumors in patients with cirrhosis tended to be larger. Peritumoral mucosal changes included loss of oxyntic glands, foveolar hyperplasia, and intestinal metaplasia. Background mucosa in group 1 patients showed PPI effect and neuroendocrine hyperplasia or dysplasia.

Conclusions

Although PPI/gastrin-associated non–type 1/2 G-NETs were smaller and more indolent than typical type 3 G-NETs, tumors in patients with cirrhosis tended to be larger. Additionally, peritumoral mucosal changes could mimic chronic atrophic gastritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsStomach NeoplasmsHumansGastrinsHyperplasiaProton Pump InhibitorsGastric Mucosa

Stichwörter der Autor:innen

cirrhosisgastric neuroendocrine tumorsmucosal changesnon–type 1 and 2proton pump inhibitor

Substanzen

GastrinsProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Pathology, Duke University Medical Center, Durham, NC, US.

ORCID-Profile: Chanjuan Shi

Zitieren

APA

Logan, K., & Shi, C. (2023). Clinicopathologic features of non–type 1/2 gastric neuroendocrine tumors and their associated mucosal changes. American Journal of Clinical Pathology, 160(2), 130-136. https://doi.org/10.1093/ajcp/aqad021

Vancouver

Logan K, Shi C. Clinicopathologic features of non–type 1/2 gastric neuroendocrine tumors and their associated mucosal changes. American Journal of Clinical Pathology. 2023;160(2):130-136. doi:10.1093/ajcp/aqad021

BibTeX
@article{Logan2023,
  author = {Logan, Kristen and Shi, Chanjuan},
  title = {Clinicopathologic features of non–type 1/2 gastric neuroendocrine tumors and their associated mucosal changes},
  journal = {American Journal of Clinical Pathology},
  year = {2023},
  volume = {160},
  number = {2},
  pages = {130--136},
  doi = {10.1093/ajcp/aqad021}
}
Kostenlos starten →